View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
The parenteral anticoagulant enoxaparin, a low-molecular-weight heparin, is widely used for prophylaxis of venous thromboembolism (VTE) following total hip replacement. New evidence indicates that a novel oral direct thrombin inhibitor, dabigatran etexilate (DE), is equally effective.
In a study involving 3,494 patients undergoing total hip replacement, researchers randomized patients to receive either 28 to 35 days of DE or subcutaneous injections of enoxaparin. Of those taking DE, about half took 220 mg and half took 150 mg once daily, starting with a half-dose 1 to 4 hours after surgery. Those receiving injections received 40 mg of enoxaparin once daily starting the evening before surgery.
Death from all causes, including VTE, occurred in 6% of patients taking 220 mg of DE, in 8.6% of patients taking 150 mg of DE, and in 6.7% of patients receiving enoxaparin. No significant differences existed between the three treatment groups in rates of VTE, bleeding, frequency of coronary events, or increased liver enzymes.
Source: Eriksson BI, et al., Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial, The Lancet, September 15, 2007.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top